Stayble Therapeutics investor relations material

Stayble Therapeutics AB develops injectable treatment for chronic low back pain triggered by disc degeneration. Its portfolio includes StaYble, a combination of two drugs that are already approved for use in humans and administered as separate mechanisms at complementary sites of action, with the goal of achieving synergy, which is the treatment of pain through several independent but related mechanisms.